|Mack, Christine - AMYLIN PHARMACEUTICALS|
|Liu, Que - AMYLIN PHARMACEUTICALS|
|Jodka, Carolyn - AMYLIN PHARMACEUTICALS|
|Young, Andrew - AMYLIN PHARMACEUTICALS|
|Parkes, David - AMYLIN PHARMACEUTICALS|
Submitted to: Drug Development Research
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: July 1, 2006
Publication Date: July 1, 2006
Repository URL: http://onlinelibrary.wiley.com/doi/10.1002/ddr.20121/pdf
Citation: Mack, C., Laugero, K.D., Liu, Q., Jodka, C., Young, A., Parkes, D. 2006. Therapeutic Applications of Incretin Mimetics for Metabolic Diseases: Preclinical Studies. Drug Development Research. 67(7):553-558, 2006. Interpretive Summary: This article outlines preclinical research results and drug discovery efforts that are helping to reveal new clinical uses of a peptide hormone class referred to as incretins. The article reviews results from preclinical research that demonstrate the potential application of incretin mimetics to prevent and treat obesity, the metabolic syndrome, hypertension, and cardiac dysfunction.
Technical Abstract: Exenatide (exendin-4) is an incretin mimetic peptide that shares several glucoregulatory actions with the endogenous incretin GLP-1. In addition to its actions on glucose control, exenatide produces effects to reduce food intake and body weight in all species studied. GLP-1 and exenatide have also been shown to modulate cardiovascular function in both animal and human studies. This overview examines the metabolic effects of exenatide beyond its antidiabetic actions, and will focus on studies with respect to obesity, hypertension, and cardiac dysfunction in preclinical models of diet-induced obesity, metabolic syndrome, and chronic heart failure.